Ashwagandha Side Effects: What the Clinical Evidence and Case Reports Show

Understanding ashwagandha side effects requires separating three distinct bodies of evidence: controlled clinical trial safety data, spontaneous case reports in pharmacovigilance databases, and traditional Ayurvedic use records. These tell a consistent but nuanced story — ashwagandha (Withania somnifera) is among the better-tolerated herbal adaptogens at standard doses in healthy adult populations, but it is not without risk. Standardized root extracts like KSM-66 have the most robust safety data; whole-plant preparations, high-dose use, and specific vulnerable populations carry meaningfully higher risk profiles. This article breaks down exactly what the evidence shows, where it is incomplete, and who should exercise caution or avoid the supplement entirely.

The Evidence Base: What Clinical Trials Show About Safety

The most reliable safety data on ashwagandha comes from randomized controlled trials using standardized root extracts. Chandrasekhar et al. (2012), the landmark stress and anxiety trial, followed 64 adults taking 300 mg/day of KSM-66 for 60 days and found no serious adverse events. Reported side effects in the treatment group were minor: one participant reported drowsiness, and GI discomfort was noted in a small number of cases — rates not significantly different from placebo. Langade et al. (2019), a sleep trial using 300 mg KSM-66 twice daily for 10 weeks in adults with insomnia, also found a favorable safety profile with no serious adverse events and no clinically significant changes in liver enzymes, kidney function, or hematological parameters.

Below is a summary of reported side effects by dose range and risk population:

Dose Range	Common Side Effects	Severity	Higher-Risk Groups
300–600 mg/day (KSM-66 / Sensoril)	Mild GI discomfort, drowsiness	Low	General population — well tolerated
600–1,200 mg/day	Loose stools, headache, increased appetite	Low–Moderate	Sensitive GI individuals
>1,200 mg/day or prolonged use	Potential liver enzyme elevation (rare case reports)	Moderate (rare)	Pre-existing liver conditions, polypharmacy
Any dose	Hormonal interaction, uterine stimulation	Moderate–High	Pregnant women, thyroid patients on medication

Wankhede et al. (2015) studied ashwagandha in healthy athletic men at 300 mg twice daily for 8 weeks — a population at higher risk from any pro-androgenic compound given training context — and found no significant adverse events. Choudhary et al. (2017) used 300 mg twice daily for 8 weeks in a cognitive performance trial with similar safety outcomes. Across these trials, the adverse event profile is modest: GI symptoms in a minority of participants, drowsiness particularly in evening dosers, and no consistent biochemical signals of harm in blood work panels.

However, clinical trial populations are selected, monitored, and relatively healthy. They exclude people on multiple medications, with pre-existing liver conditions, or with autoimmune disease — exactly the populations at higher risk for adverse effects with ashwagandha. Trial durations are also short (8–12 weeks); long-term safety data beyond 3 months is sparse. The KSM-66 Clinical Trials summary provides a comprehensive overview of the 22 trials on this specific extract, which collectively represent the strongest evidence base for any single ashwagandha product.

The Mechanism: Why Side Effects Occur

Ashwagandha’s active constituents include withanolides (steroidal lactones), alkaloids, saponins, and iron-containing compounds. The withanolides are primary drivers of both the adaptogenic effects and the side effect profile. Their structural similarity to steroid hormones means they interact with hormone receptors: ashwagandha has documented thyroid-stimulating activity (it raises T3 and T4 levels in animal and human studies), androgen-modulating properties (relevant to testosterone and DHEA effects seen in clinical trials), and adrenal effects via the HPA axis.

The hepatotoxic cases, while rare, appear related to withanolide metabolism by the cytochrome P450 system — particularly CYP2D6 and CYP3A4. In genetically susceptible individuals (poor metabolizers) or in those whose CYP enzymes are inhibited by other drugs, withanolides may accumulate and generate reactive metabolites that cause hepatocellular injury via immune-mediated or direct toxic mechanisms. The alkaloids and saponins contribute to the GI effects (nausea, diarrhea) through local irritation of the gastrointestinal mucosa at higher doses.

Common Side Effects: GI Upset and Drowsiness

The most frequently reported side effects with ashwagandha in clinical practice are gastrointestinal: nausea, loose stools, and abdominal discomfort. These are dose-dependent and most common when ashwagandha is taken on an empty stomach. The saponin and alkaloid content of root extracts, particularly at doses above 600 mg/day, irritates the gastric and intestinal mucosa directly. The solution in most cases is straightforward: take ashwagandha with food, start at a lower dose (150–300 mg/day), and build up gradually.

Drowsiness and sedation are reported particularly with evening dosing or higher doses. This is largely a feature rather than a bug — ashwagandha’s cortisol-lowering and GABA-A modulatory effects contribute to its sleep-improvement efficacy (Langade et al., 2019), but daytime dosers who are sensitive to sedating compounds may find morning alertness reduced. Scheduling the dose in the evening or at bedtime eliminates this issue for most users. Pratte et al. (2014) reviewed multiple human trials and noted that sedation is a consistent but generally mild finding at standard doses.

Rare but Serious: Liver Injury

Ashwagandha-associated hepatotoxicity is rare — the incidence in clinical trial populations appears to be negligible — but it is not hypothetical. Spontaneous case reports published in the scientific literature and pharmacovigilance databases have documented cases of drug-induced liver injury (DILI) attributed to ashwagandha supplementation. A case series review by Björnsson et al. (2020, J Hepatol) described several cases of cholestatic, hepatocellular, or mixed liver injury in patients taking ashwagandha for 2–12 weeks. Most resolved fully after discontinuation, but at least one case required hospitalization. Liver biopsies in several cases showed evidence of immune-mediated injury consistent with idiosyncratic DILI rather than dose-dependent toxicity.

The implication is important: idiosyncratic DILI means it can occur at standard doses in genetically susceptible individuals without warning signs. Risk factors identified in case reports include prolonged use beyond 12 weeks at high doses, concurrent use of hepatotoxic medications, pre-existing liver disease, and possibly genetic variation in CYP metabolizing enzymes. The absolute risk remains low — millions of people use ashwagandha without liver problems — but individuals with any liver condition, those on hepatotoxic drugs (some statins, certain antibiotics, acetaminophen at high doses), or those who consume alcohol regularly should consult a healthcare provider before use. Monitoring liver enzymes (ALT, AST) after 4–6 weeks of use is a reasonable precaution for longer-term supplementers. For guidance on selecting a quality extract with the most clinical safety data, see our How to Choose Ashwagandha guide.

Drug Interactions and Contraindications

Several drug classes have clinically relevant interactions with ashwagandha:

Thyroid medications: Ashwagandha stimulates thyroid hormone production — it increases T3 and T4 levels in human trials. In people taking levothyroxine or other thyroid medications for hypothyroidism, ashwagandha may cause dose-stacking effects, driving thyroid hormones above the therapeutic range and producing hyperthyroid symptoms (palpitations, anxiety, tremor, weight loss). Thyroid levels should be monitored if ashwagandha is added to a thyroid medication regimen. Conversely, people with hyperthyroidism should avoid ashwagandha entirely.

Sedative medications: Ashwagandha potentiates GABAergic sedation. Concurrent use with benzodiazepines (alprazolam, diazepam), barbiturates, sleep aids (zolpidem), or alcohol amplifies central nervous system depression beyond what either compound would produce alone. This is particularly relevant for anyone taking prescription anxiolytics or sleep medications.

Immunosuppressants: Ashwagandha has demonstrated immunomodulatory activity — it generally stimulates immune function, which is directionally opposite to what immunosuppressants (tacrolimus, cyclosporine, methotrexate) are trying to achieve. People who have undergone organ transplantation or who take immunosuppressants for autoimmune disease should avoid ashwagandha.

Hypoglycemic agents: Ashwagandha has mild blood-glucose-lowering effects. In diabetics on insulin or oral hypoglycemics (metformin, sulfonylureas), adding ashwagandha may lower blood glucose further, increasing hypoglycemia risk. Blood glucose should be monitored more closely when beginning ashwagandha in this population.

Thyroid and Autoimmune Considerations

The thyroid stimulatory effects of ashwagandha deserve separate attention beyond drug interactions. Multiple human trials have documented increases in serum T3 and T4 following ashwagandha supplementation at doses of 300–600 mg/day. For most healthy people without thyroid disease, this is well within physiological range and does not cause symptoms. For people with subclinical or undiagnosed hyperthyroid conditions, Hashimoto’s thyroiditis in the hyperthyroid phase, or Graves’ disease, ashwagandha may worsen the condition.

Autoimmune conditions more broadly are a theoretical concern due to immune stimulation. Ashwagandha’s immunomodulatory effects — increased NK cell activity, enhanced lymphocyte proliferation — could theoretically exacerbate autoimmune disease by amplifying the immune response against self tissue. Clinical evidence is limited, but this concern is sufficient that most integrative medicine practitioners advise caution in people with lupus, rheumatoid arthritis, multiple sclerosis, and similar conditions. This is an area where "generally well-tolerated" data from healthy populations does not straightforwardly apply.

Who Benefits Most with Minimal Risk

Based on the combined safety and efficacy evidence, ashwagandha — particularly KSM-66 standardized extract at 300–600 mg/day — has the best risk-benefit profile in:

• Healthy adults with stress, anxiety, or sleep difficulties who are not on thyroid medication, immunosuppressants, or sedatives, and who have no liver disease or autoimmune history. The Chandrasekhar et al. (2012) and Langade et al. (2019) data are directly applicable. As our Ashwagandha Anxiety Review covers, the stress-reduction evidence is among the most consistent in the adaptogen category.
• Physically active adults using ashwagandha for muscle recovery and strength (Wankhede et al., 2015), where safety data is specifically available in training populations.
• Adults with normal liver function and no concurrent hepatotoxic drug use, where the DILI risk remains very low based on the trial literature.

Higher-risk groups — pregnant and breastfeeding women (limited safety data; uterotonic effects have been reported in some preparations), those with thyroid disease, autoimmune conditions, liver disease, or on multiple medications — should consult a physician before use. Bio:sudo KSM-66 Reishi Restore uses the clinically studied KSM-66 extract, which has the most transparent safety documentation of any ashwagandha product on the market, including certificates of analysis and batch testing for withanolide content and contaminants.

Practical Takeaways

• At 300–600 mg/day of standardized root extract (KSM-66 or equivalent), ashwagandha is well-tolerated in the majority of healthy adults in clinical trial populations. The adverse event profile is minor and largely reversible.
• Always take ashwagandha with food to minimize GI side effects; the saponin content is the primary irritant and food buffering significantly reduces it.
• Liver injury is rare but documented — if you have liver disease, drink alcohol regularly, or take hepatotoxic medications, avoid ashwagandha or consult your physician first. Consider an ALT/AST check after 4–6 weeks if using long-term.
• Thyroid medication users: have your thyroid panel rechecked 4–6 weeks after starting ashwagandha. The thyroid-stimulating effects are real and can push treated hypothyroid patients into hyperthyroid range.
• Do not combine with benzodiazepines, barbiturates, or other CNS depressants — the additive sedation can be significant.
• Autoimmune conditions and immunosuppressant use are relative contraindications; consult with your prescribing physician before adding ashwagandha to the regimen.
• Prefer standardized root extracts (not leaf, not whole-plant) with documented withanolide content — these have the most safety data and the most predictable dose-response profiles.

Bottom Line

Ashwagandha’s safety record in clinical trials is genuinely good for a large majority of healthy adults — GI discomfort and mild drowsiness are the typical ceiling of adverse effects at standard doses. The rare liver injury cases are real and worth knowing about, but the absolute risk in low-risk individuals appears to be low. The more significant safety concerns involve drug interactions (thyroid medications, sedatives, immunosuppressants) and specific medical conditions (liver disease, autoimmune disorders, thyroid disease), where the trial population data does not apply. Being clear-eyed about these risks is not a reason to avoid ashwagandha for the right person — it is a reason to use it thoughtfully, with appropriate monitoring, in populations where the evidence supports a favorable risk-benefit balance.

References

1. Chandrasekhar K, et al. “A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of ashwagandha root in reducing stress and anxiety in adults.” Indian J Psychol Med. 2012;34(3):255–262. [Source]
2. Langade D, et al. “Efficacy and safety of ashwagandha root extract in insomnia and anxiety.” Medicine. 2019;98(37):e17186. [Source]
3. Wankhede S, et al. “Examining the effect of Withania somnifera supplementation on muscle strength and recovery.” J Int Soc Sports Nutr. 2015;12:43. [Source]
4. Choudhary D, et al. “Efficacy and safety of ashwagandha root extract in improving memory and cognitive functions.” J Dietary Suppl. 2017;14(6):599–612. [Source]
5. Pratte MA, et al. “An alternative treatment for anxiety: a systematic review of human trial results reported for the Ayurvedic herb ashwagandha.” J Altern Complement Med. 2014;20(12):901–908. [Source]

---

---